Mainstreaming AYUSH The last month saw a major milestone in the patent versus patient debate By Viveka RoychowdhuryUpdated: October 6, 2015 18:22 IST
Playing for high stakes According to the latest data from the India Brand Equity Foundation (IBEF), the Indian domestic pharma market ended FY15 with… By Viveka RoychowdhurySeptember 14, 2015 11:13 IST
Mylan’s One Quality Standard a long way off Some industry observers are surprised that ‘significant violations’ of this nature have not warranted an import alert or ban By Viveka RoychowdhuryAugust 24, 2015 12:34 IST
New strategies for growth After a decade of pain, there are some reassuring signs that the pharmaceutical industry may just be seeing the faint… By Viveka RoychowdhuryUpdated: August 20, 2015 12:40 IST
Digital India: A new game needs new rules With the launch of the Digital India campaign in early July, it is time to relook India Pharma Inc’s engagement… By Viveka RoychowdhuryUpdated: August 5, 2015 11:24 IST
Lee Pharma revives the CL debate With little known Lee Pharma filing India’s third compulsory licensing (CL), legal eagles and everyone interested or connected to pharmaceutical… By Viveka RoychowdhuryUpdated: July 20, 2015 17:59 IST
TRIPs-ing time again When governments have to weigh public health against IP issues, LDCs and developing countries really have no choice but to… By Viveka RoychowdhuryUpdated: July 2, 2015 16:37 IST
Data integrity … dil se Two reports, released in early June, have both good news and bad news for the pharma industry in India By Viveka RoychowdhuryJune 20, 2015 19:02 IST
Wish list for PM Modi’s second year Just as 2015 is a make or break year for PM Modi, this will be a decisive year for the… By Viveka RoychowdhuryUpdated: May 27, 2015 09:35 IST
When patience is not a virtue India once again made it to the Priority Watch list of the 2015 USTR Special 301 Report, but this year,… By Viveka RoychowdhuryMay 21, 2015 07:05 IST
Rebooting Jan Aushadhi As Prime Minister Modi completes a year in office this May, there will no doubt be many lists of this… By Viveka RoychowdhuryUpdated: May 5, 2015 11:02 IST
Good growth prospects despite headwinds As we settle into FY2016, it is worth taking a quick look at some of the earning previews of the… By Viveka RoychowdhuryUpdated: April 21, 2015 14:12 IST
Making hay while the Sun shines Success hinges on the company getting its GMP right and surviving the glare of regulatory scrutiny By Viveka RoychowdhuryMarch 27, 2015 14:45 IST
Intent right, but implementation is key Finance Minister Arun Jaitley’s first Union Budget had nothing special for the pharmaceutical industry By Viveka RoychowdhuryUpdated: March 23, 2015 10:28 IST
Policy pinings As in previous years, we mark this Women’s Day with a cover story section devoted to women’s health issue By Viveka RoychowdhuryMarch 6, 2015 15:34 IST
The politics of IPR policy The draft National IPR policy, unveiled last December by the Department of Industrial Policy & Promotion (DIPP), has already garnered… By Viveka RoychowdhuryFebruary 20, 2015 19:32 IST
The bigger picture vs the nitty-gritty While we are urged to look beyond the sticky issues, one cannot overlook the final impact of decisions on India’s… By Viveka RoychowdhuryUpdated: January 29, 2015 12:42 IST
Could a surgeon become DCG(I)? CDSCO’s planned ‘harmonisation of recruitment rules’ is sure to resurrect this debate By Viveka RoychowdhuryJanuary 16, 2015 12:44 IST
How will markets open today? Dow Jones up, GIFT Nifty in green, and 6 other cues to watch at this hour
11 Photos Bollywood put their glam game on, at Manish Malhotra’s Diwali bash 2025 | In Pictures 2 weeks agoOctober 13, 2025
9 Photos PM Modi inaugurates Phase 1 of the Navi Mumbai International Airport | In pictures 3 weeks agoOctober 8, 2025
11 Photos In Images | Delhi struggles with waterlogging as rains hit festival season plans 4 weeks agoSeptember 30, 2025
